Terms: = Breast cancer AND B2M, P61769, 567, ENSG00000166710 AND Clinical Outcome
5 results:
1. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted cancer Therapy.
Wang T; Philippovich S; Mao J; Veedu RN
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546749
[TBL] [Abstract] [Full Text] [Related]
2. S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells.
Kikuchi K; McNamara KM; Miki Y; Iwabuchi E; Kanai A; Miyashita M; Ishida T; Sasano H
Cell Oncol (Dordr); 2019 Feb; 42(1):67-80. PubMed ID: 30244410
[TBL] [Abstract] [Full Text] [Related]
3. Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
De Placido S; De Angelis C; Giuliano M; Pizzi C; Ruocco R; Perrone V; Bruzzese D; Tommasielli G; De Laurentiis M; Cammarota S; Arpino G; Arpino G
Br J Cancer; 2017 Mar; 116(6):821-827. PubMed ID: 28170371
[TBL] [Abstract] [Full Text] [Related]
4. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules.
Teschendorff AE; Gomez S; Arenas A; El-Ashry D; Schmidt M; Gehrmann M; Caldas C
BMC Cancer; 2010 Nov; 10():604. PubMed ID: 21050467
[TBL] [Abstract] [Full Text] [Related]
5. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract] [Full Text] [Related]
